HOME / INVESTORS / BOARD OF DIRECTORS AND CEO

Kurt Nilsson
Chairman of the board.
Member of the board since 1996.
Born 1953. Founder of Glycorex Transplantation AB and R&D Manager. Doctor of Engineering in chemistry and applied biochemistry at Lund University. Senior lecturer in biotechnology.
Shareholding including related parties: 3,268,000 A restricted shares and 3,979,051 B unrestricted shares. 

Christer Ahlberg
Member of the board since 2020.
Born 1971.
Christer holds a BSc in business administration and economics from Örebro University. President and Chief Executive Officer of Sedana Medical since February 2017. Former experience in the pharmaceutical industry includes CEO at Unimedic Group (2010–2016), CEO at Eisai AB (2005–2010) and more than 10 years of experience in leading positions in sales and marketing at e.g. AstraZeneca, Meda and Wyeth.
Other current engagements: Board member in FrostPharma AB and Prooxpharma AB. CEO and deputy board member in Waxholm by the sea aktiebolag.
Shareholding: 60,000 B unrestricted shares.

Nils Siegbahn 
Member of the board since 2021 (member and chairman of the company 2000-2009).
Born 1953.
Doctor of Technology in Chemistry and Applied Biochemistry at Lund University and M.Sc in Business and Economics at Stockholm School of Economics. Experience in research, former Marketing Director at Nicoretteand, CEO of several PerstorpB companies, Atos Medical, Pernovo, Alligator Bioscience and Niconovum. Management consultant at ACH Consultant (ongoing). Member of Sparbanksstiftelsen Syd Riskkapitalstyrelse, Celltrix AB and CanImGudie
Shareholding: 0 shares

Torbjörn Axelsson
Member of the board since 2021.
Born 1960.
M.Sc.in Business and Economics at Lund University with more than 30 years of experience from various positions in economics and finance in several different industries, most recently as CFO at Bona AB.
Shareholding: 0 shares

Tomas Westergren
Deputy member of the board since 2012.
Born 1964.
Master of Engineering, physician and doctor of philosophy in biochemistry, experience of research and clinical work with patients.
Shareholding: 1,560,000 B unrestricted shares